Home > Journals > Panminerva Medica > Past Issues > Panminerva Medica 2022 March;64(1) > Panminerva Medica 2022 March;64(1):1-8



Publishing options
To subscribe
Submit an article
Recommend to your librarian


Publication history
Cite this article as



Panminerva Medica 2022 March;64(1):1-8

DOI: 10.23736/S0031-0808.21.04497-9


language: English

Implantation of one, two or multiple MitraClip™ for transcatheter mitral valve repair: insights from a 1824-patient multicenter study

Arturo GIORDANO 1, Paolo FERRARO 2, Filippo FINIZIO 1, Giuseppe BIONDI-ZOCCAI 3, 4 , Paolo DENTI 5, Francesco BEDOGNI 6, Antonio P. RUBBIO 6, Anna S. PETRONIO 7, Antonio L. BARTORELLI 8, Annalisa MONGIARDO 9, Salvatore GIORDANO 9, Francesco DE FELICE 10, Marianna ADAMO 11, Matteo MONTORFANO 12, Cesare BALDI 13, Giuseppe TARANTINI 14, Francesco GIANNINI 15, Federico RONCO 16, Ida MONTEFORTE 17, Emmanuel VILLA 18, Maurizio FERRARIO 19, Luigi FIOCCA 20, Fausto CASTRIOTA 21, Corrado TAMBURINO 22

1 Operative Unit for Cardiovascular Interventions, Pineta Grande Hospital, Castel Volturno, Caserta, Italy; 2 Unit of Hemodynamics, Santa Lucia Hospital, San Giuseppe Vesuviano, Naples, Italy; 3 Department of Medico-Surgical Sciences and Biotechnologies, Sapienza University, Latina, Italy; 4 Mediterranea Cardiocentro, Naples, Italy; 5 Department of Cardiac Surgery, IRCCS San Raffaele Hospital, Vita-Salute San Raffaele University, Milan, Italy; 6 Department of Cardiology, IRCCS San Donato Polyclinic, San Donato Milanese, Milan, Italy; 7 Cardiothoracic and Vascular Department, University Hospital of Pisa, Pisa, Italy; 8 Luigi Sacco Department of Biomedical and Clinical Sciences, Centro Cardiologico Monzino IRCCS, University of Milan, Milan, Italy; 9 Division of Cardiology, Department of Medical and Surgical Sciences, The Magna Græcia University of Catanzaro, Catanzaro, Italy; 10 Division of Interventional Cardiology, S. Camillo Forlanini Hospital, Rome, Italy; 11 Cardiothoracic Department, Spedali Civili Brescia, Brescia, Italy; 12 Cardio-Thoracic-Vascular Department, IRCCS San Raffaele Hospital, Milan, Italy; 13 Heart Department, Scuola Medica Salernitana University Hospital, Salerno, Italy; 14 Unit of Interventional Cardiology, Department of Cardiac, Thoracic and Vascular Science, University of Padua, Padua, Italy; 15 Unit of Interventional Cardiology, GVM Care & Research, Maria Cecilia Hospital, Cotignola, Ravenna, Italy; 16 Unit of Interventional Cardiology, Department of Cardio-Thoracic and Vascular Sciences, dell’Angelo Hospital, AULSS3 Serenissima, Mestre, Venice, Italy; 17 Division of Cardiology, AORN dei Colli - Monaldi Hospital, Naples, Italy; 18 Department of Cardiac Surgery, Poliambulanza Foundation Hospital, Brescia, Italy; 19 Division of Cardiology, Foundation IRCCS Polyclinic S. Matteo, Pavia, Italy; 20 Cardiovascular Department, Papa Giovanni XXIII Hospital, Bergamo, Italy; 21 Cardiovascular Department, Humanitas Gavazzeni Hospital, Bergamo, Italy; 22 Division of Cardiology, Centro Alte Specialità e Trapianti (CAST), Vittorio Emanuele Polyclinic, University of Catania, Catania, Italy

BACKGROUND: Transcatheter mitral valve repair (TMVR) with MitraClip™ (Abbott Laboratories; Abbott Park, IL, USA) is an established treatment for mitral regurgitation (MR). More than one MitraClip™ may be implanted if a single one does not reduce MR adequately. We aimed to appraise the outlook of patients undergoing implantation of one, two or multiple MitraClip™ for TMVR.
METHODS: Exploiting the ongoing prospective GISE Registry of Transcatheter Treatment of Mitral Valve Regurgitation (GIOTTO) Study dataset, we compared patients, procedural details and outcomes distinguishing those receiving one, two or multiple MitraClip™. The primary endpoint was the composite of 1-year cardiac death or rehospitalization for heart failure. Additional endpoints included all cause death, surgical mitral repair, and functional class. Multivariable adjusted Cox proportional hazard analysis was used for confirmatory purposes.
RESULTS: As many as 1824 patients were included: 718 (39.4%) treated with a single MitraClip™, and 940 (51.5%) receiving two MitraClip™, and 166 (9.1%) receiving three or more. Significant differences were found for baseline features, including age, female gender, diabetes mellitus, hypertension, chronic obstructive pulmonary disease, prior myocardial infarction, atrial fibrillation, permanent pacemaker, cardiac resynchronization therapy, implantable cardioverter defibrillator, and prior mitral valve repair (all P<0.05). Several imaging features were also different, including left ventricular dimensions, MR severity and proportionality, mitral valve area, flail leaflet, and pulmonary vein flow (all P<0.05). Among procedural features, significant differences were found for anesthesia type, MitraClip™ type, fluoroscopy, device, and operating room times, postprocedural mitral gradient, residual MR, smoke-like effect, device success partial detachment and surgical conversion (all P<0.05). In-hospital death occurred more frequently in patients receiving multiple MitraClip™, and the same applied severe residual MR (all P<0.05). Mid-term follow-up (15±13 months) showed significant differences in the risk of death, cardiac death, rehospitalization for heart failure, and their composites, mainly, but not solely, associated with multiple MitraClip™ (all P<0.05). Adjusted analysis confirmed the significantly increased risk of composite adverse events when comparing the multiple vs. single MitraClip™ groups (P=0.014 for death and rehospitalization, P=0.013 for cardiac death or rehospitalization).
CONCLUSIONS: Implantation of one or two MitraClip™ is associated with favorable clinical outcomes. Conversely, bail-out implantation of three or more MitraClip™ may portend a worse long-term prognosis.

KEY WORDS: Heart diseases; Mitral valve insufficiency; Mitral valve annuloplasty

top of page